Trials / Completed
CompletedNCT02142400
Multiple Ascending Dose Study of DS-1093 in Healthy Subjects
A Double Blind, Randomised, Placebo-controlled, Multiple Ascending-dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of DS 1093a in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a randomised, double-blind, placebo-controlled multiple ascending single study. It is hypothesised that at least dose of DS-1093a will be safe and tolerable over a 2-week treatment period and will result in increases in reticulocyte count and haemoglobin concentrations in healthy male volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DS-1093 | DS-1093 in capsules with 2.5mg or 25mg per capsule |
| DRUG | placebo | matching placebo capsules to DS-1093 capsules |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2014-05-20
- Last updated
- 2018-12-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02142400. Inclusion in this directory is not an endorsement.